Kenneth Krogulski Acquires 3,300 Shares of Cumberland Pharmaceuticals, Inc. (CPIX) Stock

Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) Director Kenneth Krogulski acquired 3,300 shares of the stock in a transaction dated Monday, November 20th. The shares were bought at an average price of $7.55 per share, with a total value of $24,915.00. Following the completion of the purchase, the director now directly owns 154,300 shares of the company’s stock, valued at approximately $1,164,965. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of Cumberland Pharmaceuticals, Inc. (CPIX) opened at $7.66 on Friday. Cumberland Pharmaceuticals, Inc. has a one year low of $5.16 and a one year high of $7.96. The company has a current ratio of 4.18, a quick ratio of 3.81 and a debt-to-equity ratio of 0.12.

Large investors have recently bought and sold shares of the company. Essex Investment Management Co. LLC lifted its stake in shares of Cumberland Pharmaceuticals by 45.8% during the second quarter. Essex Investment Management Co. LLC now owns 15,959 shares of the specialty pharmaceutical company’s stock worth $112,000 after buying an additional 5,014 shares during the period. Ameriprise Financial Inc. lifted its stake in shares of Cumberland Pharmaceuticals by 0.3% during the second quarter. Ameriprise Financial Inc. now owns 23,892 shares of the specialty pharmaceutical company’s stock worth $167,000 after buying an additional 80 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Cumberland Pharmaceuticals by 5.2% during the first quarter. Renaissance Technologies LLC now owns 270,240 shares of the specialty pharmaceutical company’s stock worth $1,875,000 after buying an additional 13,240 shares during the period. Vanguard Group Inc. lifted its stake in shares of Cumberland Pharmaceuticals by 0.4% during the second quarter. Vanguard Group Inc. now owns 298,635 shares of the specialty pharmaceutical company’s stock worth $2,111,000 after buying an additional 1,180 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Cumberland Pharmaceuticals by 1.3% during the first quarter. Dimensional Fund Advisors LP now owns 863,819 shares of the specialty pharmaceutical company’s stock worth $5,995,000 after buying an additional 10,843 shares during the period. Institutional investors and hedge funds own 34.53% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://transcriptdaily.com/2017/11/26/kenneth-krogulski-acquires-3300-shares-of-cumberland-pharmaceuticals-inc-cpix-stock.html.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (Cumberland) is a specialty pharmaceutical company. The Company is focused on the acquisition, development and commercialization of branded prescription products. The Company operates through specialty pharmaceutical products segment. The Company’s product portfolio includes Acetadote (acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) Injection for the treatment of pain and fever; Kristalose (lactulose) for Oral Solution for the treatment of chronic and acute constipation; Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H.

Receive News & Ratings for Cumberland Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cumberland Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply